Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL
Recruiting
Observational Study
DLBCL - Diffuse Large B Cell Lymphoma
Markers of Inflammation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Study type
- Observational
- Participants needed
- 40 (estimated)
- Sponsor
- Ain Shams University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 18 years and ≤ 65 years
* Pathologically confirmed, treatment-naïve diffuse large B-cell lymphoma (DLBCL)
* Any stage of disease (nodal or extra-nodal), with or without B symptoms
* Scheduled to receive standard systemic treatment (R-CHOP)
* ECOG performance status 0-2
*…
Contacts